Cibc World Market Inc. acquired a new stake in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 16,794 shares of the medical instruments supplier’s stock, valued at approximately $6,029,000.
A number of other large investors also recently bought and sold shares of WST. Addison Advisors LLC acquired a new stake in West Pharmaceutical Services in the second quarter valued at about $28,000. Avalon Trust Co purchased a new stake in West Pharmaceutical Services in the 2nd quarter valued at approximately $28,000. Elyxium Wealth LLC acquired a new position in West Pharmaceutical Services during the 4th quarter worth approximately $25,000. Bayban purchased a new position in shares of West Pharmaceutical Services during the 4th quarter worth approximately $27,000. Finally, DV Equities LLC purchased a new position in shares of West Pharmaceutical Services during the 4th quarter worth approximately $28,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.
West Pharmaceutical Services Stock Performance
Shares of WST stock opened at $348.97 on Wednesday. The stock has a fifty day moving average price of $349.44 and a 200 day moving average price of $301.84. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. The stock has a market cap of $24.56 billion, a PE ratio of 44.68, a P/E/G ratio of 2.47 and a beta of 1.15. West Pharmaceutical Services, Inc. has a 1 year low of $223.83 and a 1 year high of $386.00.
West Pharmaceutical Services Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were given a $0.22 dividend. The ex-dividend date was Wednesday, July 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. West Pharmaceutical Services’s dividend payout ratio is currently 11.27%.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on WST. Stephens reaffirmed an “overweight” rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Evercore restated an “outperform” rating and set a $425.00 target price on shares of West Pharmaceutical Services in a research report on Monday, July 27th. BNP Paribas Exane started coverage on shares of West Pharmaceutical Services in a research note on Monday, July 13th. They set an “outperform” rating and a $447.00 price target on the stock. Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $310.00 to $400.00 in a research note on Tuesday, June 9th. Finally, Wolfe Research initiated coverage on shares of West Pharmaceutical Services in a report on Monday, June 1st. They set an “outperform” rating and a $375.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $368.08.
Check Out Our Latest Research Report on West Pharmaceutical Services
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.
In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.
Featured Stories
- Five stocks we like better than West Pharmaceutical Services
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Free Report).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
